Skip to main content
main-content

Editor's pick

05-08-2020 | Osteoarthritis | Highlight | News

IL-1 inhibition warrants further investigation for osteoarthritis

Treatment with the IL-1β inhibitor canakinumab is associated with a reduced incidence of total joint replacement, suggests an exploratory analysis of the CANTOS trial.

Managing psoriatic arthritis in resource-limited settings

Psoriatic arthritis specialists practicing in different parts of the world discuss the challenges associated with managing the disease in resource-limited settings, and outline what the research priorities should be.

10-08-2020 | COVID-19 | News

‘Inconclusive’ evidence for the use of rheumatology drugs to treat COVID-19

Findings from a systematic review and meta-analysis suggest that hydroxychloroquine is not associated with benefits or harms in terms of COVID-19 mortality, and more studies are needed to establish whether other rheumatology drugs could be used to treat the disease.

Latest from across the site

12-08-2020 | Gout | News

Wearable activity trackers could highlight gout flares

The authors of a proof-of-concept study have demonstrated the feasibility of using wearable devices to measure changes in patterns of physical activity that may be indicative of gout flares.

11-08-2020 | COVID-19 | News

Systemic autoimmune conditions linked to severe COVID-19 disease course

Patients with systemic autoimmune conditions may have a higher risk for a severe COVID-19 disease course than those with chronic inflammatory arthritis, researchers report.

11-08-2020 | Rheumatoid arthritis | News

​​​​​​​RA linked to reduced type 2 diabetes risk

Patients with rheumatoid arthritis have a lower risk for developing type 2 diabetes relative to individuals without the disease and those with hypertension, osteoarthritis, or psoriatic arthritis, US researchers report.

10-08-2020 | COVID-19 | News

‘Inconclusive’ evidence for the use of rheumatology drugs to treat COVID-19

Findings from a systematic review and meta-analysis suggest that hydroxychloroquine is not associated with benefits or harms in terms of COVID-19 mortality, and more studies are needed to establish whether other rheumatology drugs could be used to treat the disease.

07-08-2020 | Rheumatoid arthritis | News

Infliximab presurgery ‘treatment gap’ unnecessary in RA patients

Contrary to concerns, withholding treatment with infliximab prior to surgery does not significantly impact infection or mortality risk in older patients with rheumatoid arthritis (RA), shows a study of patients undergoing cardiovascular or serious bowel surgery.

06-08-2020 | Systemic lupus erythematosus | News

Belimumab an ‘appropriate’ option for childhood-onset SLE

The addition of belimumab to standard therapy improves response rates and has manageable toxicity in patients with childhood-onset systemic lupus erythematosus, suggest findings from the phase 2 PLUTO study.

Latest from us on Twitter

Trending this week

Meet our Editorial Board

New Content Item Meet our Advisory Board

Image Credits